Ra Pharmaceuticals (RARX) Releases Earnings Results, Beats Expectations By $0.01 EPS

Ra Pharmaceuticals (NASDAQ:RARX) released its earnings results on Wednesday. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.01, Bloomberg Earnings reports.

Ra Pharmaceuticals traded down $0.08, reaching $10.88, on Friday, according to MarketBeat. 252,803 shares of the company’s stock were exchanged, compared to its average volume of 239,203. The firm has a market capitalization of $325.13 million, a PE ratio of -4.65 and a beta of 1.90. Ra Pharmaceuticals has a twelve month low of $4.78 and a twelve month high of $17.90.

A number of analysts have recently commented on the stock. Credit Suisse Group boosted their target price on shares of Ra Pharmaceuticals from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday. Raymond James assumed coverage on shares of Ra Pharmaceuticals in a research report on Thursday, June 28th. They set an “outperform” rating and a $18.00 price target on the stock. ValuEngine upgraded shares of Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, July 6th. BidaskClub upgraded shares of Ra Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 16th. Finally, BMO Capital Markets assumed coverage on shares of Ra Pharmaceuticals in a research report on Friday, July 20th. They set an “outperform” rating and a $20.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Ra Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $17.92.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Recommended Story: How Do You Make Money With Penny Stocks?

Earnings History for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply